Roka Bioscience, Inc. (ROKA)

[ash111]

ROKA DD: 12/13/2016 – Roth Capital began new coverage on Roka Bioscience, Inc. giving the company a “buy” rating. They now have a USD 10 price target on the stock.

10Q:
"As of September 30, 2016 , the Company had cash and cash equivalents and marketable securities of $30.9 million compared with $32.3 million at December 31,
2015".

About 5m O/S a/o today, cash/share about $6 :

 a   1:10   reverse stock split of the Issuer’s Shares effected on October 11, 2016.   The number of shares outstanding of the registrant’s common stock, par value of $0.001 per share, as of November 1, 2016 was 1,841,121 .

11/10/16- "the remaining outstanding Series A Preferred Stock automatically converted
into an aggregate of approximately 3,161,583 shares of common stock".

59% Ownership: http://www.nasdaq.com/symbol/roka/ownership-summary

As of September 30, 2016, the Company had 49 instruments placed with customers under commercial agreements compared to 46 instruments as of June 30, 2016.